I.V Papavrine for Labor Induction in Term PROM
ConditionPremature Rupture of Membranes
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorWestern Galilee Hospital-Nahariya
About this trial
This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo
Eligibility criteria
Qualifiers
• Singleton pregnancy
Term gestation (37-42 weeks)
Term PROM prior to active labor
Duration of PROM <12 hours at enrollment
Disqualifiers
• Multiple gestation
Previous cesarean delivery
Major fetal anomalies
Contraindication to vaginal delivery
Trial design
Treatments tested in this trial
- Papaverine arm
- Placebo
Treatment groups
110 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov